Clinical trial
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
NCT00069238 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00069238 |
|---|---|
| Title | Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas |
| Official title | Phase 2 Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, T-Cell, Extranodal NK-T-Cell |
| Intervention type | Biological, Drug |
| Interventions | Alemtuzumab (Campath), EPOCH |
| Enrollment | 31 |
| Start date | Sep 19, 2003 |
| Primary completion | Jun 11, 2009 |
| Completion | Mar 17, 2021 |
| First posted | Sep 18, 2003 |
| Last update posted | Feb 24, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: